Business
Jaguar Health Reports 2024 Financials: 2024 Net Revenue Up Approximately 20% Over 2023
The total net revenue for the year ended December 31, 2024 of approximately $11.7 million for prescription and non-prescription products, including license revenue, increased approximately 20% versus net revenue of $9.8 million for the year ended ...
About this update from Jaguar Health, Inc.
[{"type":"text","content":"The total net revenue for the year ended December 31, 2024 of approximately $11.7 million for prescription and non-prescription products, including license revenue, increased approximately 20% versus net revenue of $9.8 million for the year ended December 31, 2023","length":264,"tagName":"p"},{"type":"text","content":"The total net Q4 2024 revenue of approximately $3.5 million for prescription and non-prescription products, including license revenue, increased approximately 13% versus net Q3 2024 revenue of $3.1 million and 53% versus net Q4 2023 revenue of $2.3 million","length":256,"tagName":"p"},{"type":"text","content":"Jaguar expects first results in Q2 2025 of proof-of-concept (POC) investigator-initiated trials (IIT) of crofelemer for the rare diseases short bowel syndrome with intestinal failure and microvillus inclusion disease, with additional POC IIT results expected throughout 2025","length":274,"tagName":"p"},{"type":"text","content":"FDA meeting in the second quarter of 2025 on the statistically significant results of the Phase 3 OnTarget trial of crofelemer in the prespecified subgroup of patients with breast cancer","length":186,"tagName":"p"},{"type":"text","content":"REMINDER: Jaguar to host investor webcast Monday, March 31st at 8:30 a.m. Eastern regarding Q4 2024 financials and company updates; Click here to register for webcast","length":166,"tagName":"p"},{"type":"text","content":"SAN FRANCISCO, CA / ACCESS Newswire / March 31, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today reported consolidated financial results for the year ended December 31, 2024.","length":220,"tagName":"p"},{"type":"text","content":"The total net revenue for the Company's prescription products (Mytesi®, Gelclair®, and Canalevia®-CA1), non-prescription products, and license revenue was approximately $11.7 million in the year 2024, representing an increase of approximately 20% versus the total net revenue in the year 2023, which totaled approximately $9.8 million. The total net revenue for the Company's prescription products, non-prescription products, and license revenue was approximately $3.5 million in the fourth quarter of 2024, representing an increase of 13% over the total net revenue in the third quarter of 2024, which totaled approximately $3.1 million, and an increase of ap...